NYSE:EW Edwards Lifesciences (EW) Stock Price, News & Analysis $89.56 +2.61 (+3.01%) Closing price 03:59 PM EasternExtended Trading$89.50 -0.06 (-0.07%) As of 07:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Edwards Lifesciences Stock (NYSE:EW) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Edwards Lifesciences alerts:Sign Up Key Stats Today's Range$87.00▼$90.9950-Day Range$77.11▼$88.5652-Week Range$72.30▼$90.99Volume4.51 million shsAverage Volume4.84 million shsMarket Capitalization$51.57 billionP/E Ratio47.64Dividend YieldN/APrice Target$95.96Consensus RatingModerate Buy Company Overview Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery. In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams. The company also produces hemodynamic monitoring platforms and consumables intended for perioperative and intensive care settings to support patient management during high-acuity procedures. Customers include hospitals and health systems across multiple geographies, and Edwards distributes its products globally in markets such as North America, Europe and the Asia-Pacific region. Edwards Lifesciences has a long-standing emphasis on research, clinical evidence and product innovation, pursuing clinical trials and regulatory approvals to expand indications for existing therapies and to develop new treatments for other forms of structural heart disease. Its business model combines manufacturing, direct sales and partnerships to support training, clinical adoption and post-market surveillance. The company’s strategic focus remains on advancing less-invasive cardiac therapies and improving outcomes for patients with valvular and critical cardiovascular conditions.AI Generated. May Contain Errors. Read More Edwards Lifesciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks66th Percentile Overall ScoreEW MarketRank™: Edwards Lifesciences scored higher than 66% of companies evaluated by MarketBeat, and ranked 194th out of 849 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.0 / 5Analyst RatingModerate Buy Consensus RatingEdwards Lifesciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.81, and is based on 3 strong buy ratings, 16 buy ratings, 8 hold ratings, and no sell ratings.Upside/DownsideThe consensus price target for Edwards Lifesciences is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageEdwards Lifesciences has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Edwards Lifesciences' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings Growth12.00% Earnings GrowthEarnings for Edwards Lifesciences are expected to grow by 12.00% in the coming year, from $3.00 to $3.36 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Edwards Lifesciences is 47.64, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 38.85.Price to Earnings Ratio vs. SectorThe P/E ratio of Edwards Lifesciences is 47.64, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 25.14.Price to Earnings Growth RatioEdwards Lifesciences has a PEG Ratio of 2.15. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioEdwards Lifesciences has a P/B Ratio of 5.03. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Edwards Lifesciences' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.12% of the float of Edwards Lifesciences has been sold short.Short Interest Ratio / Days to CoverEdwards Lifesciences has a short interest ratio ("days to cover") of 2.32, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Edwards Lifesciences has recently increased by 6.75%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEdwards Lifesciences does not currently pay a dividend.Dividend GrowthEdwards Lifesciences does not have a long track record of dividend growth. News and Social Media3.9 / 5News Sentiment1.20 News SentimentEdwards Lifesciences has a news sentiment score of 1.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 15 news articles for Edwards Lifesciences this week, compared to 7 articles on an average week.Search InterestOnly 9 people have searched for EW on MarketBeat in the last 30 days. This is a decrease of -10% compared to the previous 30 days.MarketBeat Follows3 people have added Edwards Lifesciences to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Edwards Lifesciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,683,255.00 in company stock.Percentage Held by Insiders0.31% of the stock of Edwards Lifesciences is held by insiders.Percentage Held by Institutions79.46% of the stock of Edwards Lifesciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Edwards Lifesciences' insider trading history. Receive EW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Edwards Lifesciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. EW Stock News HeadlinesBeta Bionics (NASDAQ:BBNX) & Edwards Lifesciences (NYSE:EW) Critical AnalysisJune 23 at 4:18 AM | americanbankingnews.comHere's How Macro Trends and Currency Headwind Restrict GMED's GrowthJune 22 at 3:28 PM | finance.yahoo.comYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today.June 24 at 1:00 AM | Profits Run (Ad)Pacific Defense Launches Dual-Enclave 100G Ethernet Switch for Secure Multi-Mission C5ISR and Electronic Warfare SystemsJune 22 at 7:01 AM | businesswire.comEdwards Lifesciences Corporation (NYSE:EW) Receives Consensus Rating of "Moderate Buy" from AnalystsJune 18, 2026 | americanbankingnews.comEdwards Lifesciences hits 52-week high after Medicare coverage proposalJune 16, 2026 | seekingalpha.comStocks Indexes Finish Mostly Lower as Chipmakers RetreatJune 16, 2026 | barchart.comInsider Selling: Edwards Lifesciences (NYSE:EW) VP Sells 23,145 Shares of StockMay 28, 2026 | insidertrades.comSee More Headlines EW Stock Analysis - Frequently Asked Questions How have EW shares performed this year? Edwards Lifesciences' stock was trading at $85.26 at the beginning of the year. Since then, EW shares have increased by 5.0% and is now trading at $89.5630. How were Edwards Lifesciences' earnings last quarter? Edwards Lifesciences Corporation (NYSE:EW) released its quarterly earnings data on Thursday, April, 23rd. The medical research company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.73 by $0.05. The company's revenue for the quarter was up 16.7% on a year-over-year basis. Read the conference call transcript. When did Edwards Lifesciences' stock split? Edwards Lifesciences shares split on Friday, May 29th 2020.The 3-1 split was announced on Thursday, May 7th 2020. The newly issued shares were distributed to shareholders after the closing bell on Monday, May 18th 2020. An investor that had 100 shares of stock prior to the split would have 300 shares after the split. Does Edwards Lifesciences have any subsidiaries? The following companies are subsidiaries of Edwards Lifesciences: CAS Medical Systems, Harpoon Medical, Valtech Cardio, CardiAQ Valve Technologies, BMEYE, Embrella Cardiovascular, Myocor, and others. Who are Edwards Lifesciences' major shareholders? Top institutional shareholders of Edwards Lifesciences include Bank of New York Mellon Corp (2.90%), Jennison Associates LLC (2.27%), Bank of America Corp DE (0.67%) and Dimensional Fund Advisors LP (0.63%). Insiders that own company stock include Larry L Wood, Jean-Luc M Lemercier, Donald E Bobo Jr, Kieran Gallahue, Steven R Loranger, Bernard J Zovighian, Daniel J Lippis, Scott B Ullem, Catherine M Szyman, Daveen Chopra, Heisz Leslie Stone, Andrew M Dahl, Robert WA Sellers, Wayne Markowitz and Michael A Mussallem. View institutional ownership trends. How do I buy shares of Edwards Lifesciences? Shares of EW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Edwards Lifesciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Edwards Lifesciences investors own include Comcast (CMCSA), Chevron (CVX), Bristol Myers Squibb (BMY), Charles Schwab (SCHW), McKesson (MCK), Yum! Brands (YUM) and Toronto Dominion Bank (TD). Company Calendar Last Earnings4/23/2026Today6/24/2026Next Earnings (Estimated)7/23/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (4m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 EW's financial health is in the Green zone, according to TradeSmith. EW has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry MED INSTRUMENTS Sub-IndustryHealth Care Equipment Current SymbolNYSE:EW CIK1099800 Webwww.edwards.com Phone(949) 250-2500Fax949-250-2525Employees16,000Year Founded1958Price Target and Rating Average Price Target for Edwards Lifesciences$95.96 High Price Target$110.00 Low Price Target$81.00 Potential Upside/Downside+7.1%Consensus RatingModerate Buy Rating Score (0-4)2.81 Research Coverage27 Analysts Profitability EPS (Trailing Twelve Months)$1.88 Trailing P/E Ratio47.64 Forward P/E Ratio29.85 P/E Growth2.15Net Income$1.07 billion Net Margins17.39% Pretax Margin20.59% Return on Equity15.19% Return on Assets11.71% Debt Debt-to-Equity Ratio0.06 Current Ratio4.42 Quick Ratio3.63 Sales & Book Value Annual Sales$6.07 billion Price / Sales8.50 Cash Flow$2.97 per share Price / Cash Flow30.12 Book Value$17.81 per share Price / Book5.03Miscellaneous Outstanding Shares575,800,000Free Float574,015,000Market Cap$51.57 billion OptionableOptionable Beta0.87 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce. Get This Free Report This page (NYSE:EW) was last updated on 6/24/2026 by MarketBeat.com Staff. From Our PartnersThe 0DTE trade most investors get wrongZero-days-to-expiration trades happen every single day - and most traders either ignore them or use them wrong...Base Camp Trading | SponsoredFirm That Predicted 2008, 2020, 2022: Right Now Looks WorseThe firm that predicted the dot-com crash, the 2008 financial crisis, the 2020 COVID crash, and the 2022 bear ...TradeSmith | SponsoredThe Treasury just bought its own debtOn April 16th, the U.S. Treasury executed a $15 billion buyback of its own debt - the largest in history - whi...Golden Portfolio | SponsoredBlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely, LLC | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...Weiss Ratings | SponsoredMy feud with Zohran MamdaniNearly 40% of Americans now hold a positive view of socialism - and former hedge fund manager Whitney Tilson s...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Edwards Lifesciences Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Edwards Lifesciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
